Safety, Tolerability, and Exploratory Efficacy of AGP100 in Patients With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

NCT07263139 | Recruiting Phase 2 DMC

• 2 other identifiers: AGP100-C012025-521611-39-00
• Study Type: interventional
• Target: 10
• Locations: 1 country
• Sites: 1

Brief Summary

This trial is conducted in patients with an inherited heart rhythm disorder called catecholaminergic polymorphic ventricular tachycardia (CPVT). This condition causes the heart to beat dangerously fast during situations of physical or emotional stress. CPVT is a serious condition that can limit the length and quality of patients' lives. Current treatment does not always prevent the abnormal heart rhythms that can occur as part of CPVT during strenuous exercise or stress, so new and improved medications are needed. The main questions that the trial will answer are:

• How safe and tolerable is the drug AGP100; i.e, what medical problems do patients experience when taking the drug?
• Does the drug help CPVT patients to maintain a normal heart rhythm while they are exercising?
• How does the drug affect the levels of key heart cell signalling molecules? Patients with a diagnosis of CPVT who are aged between 18 and 75 and experience abnormal heart rhythms during exercise, despite taking a stable dose of the medication(s) prescribed by their doctor for their CPVT can take part in this trial. Participants should have normal kidney and liver function and not have high blood pressure or a diagnosis of structural heart disease. Women who are pregnant or breastfeeding cannot take part in the study. Participants who may become pregnant (and their partners) need to use highly effective methods of contraception during the study and for 90 days after the study ends. Participants will take part in the study for ten weeks. During this time, participants will be asked to take three different doses of the the drug (AGP100), as well as their normal heart medication. The drug is an oral capsule and each different dose will be taken once a day for 13 days. The study starts with participants taking a low dose for 2 weeks, then a medium dose and then a high dose. At each dose, participants will undergo a clinical examination, report any potential side effects and the treating doctor will investigate the safety, tolerability and side effects of AGP100. In total, participants will take AGP100 once a day for about six weeks. The last four weeks of the study will be a follow-up period where participants will not take AGP100. During the study, participants will need to visit the hospital six times. The visits will be three outpatient appointments and three overnight stays.

Conditions

Catecholaminergic Polymorphic Ventricular Tachycardia

Outcome Measures

Primary Outcomes (7)

• Incidence of adverse events (AEs)

  From Day 1 (start of treatment) through Day 68 [EoS])

• Changes in heart rate (HR)

  Unit: beats per minute (bpm)

  Day 1, Day 2, Day 14, Day 15, Day 27, Day 28, Day 39 (End of Treatment), and Day 68 (EoS)

• Changes in 12-lead electrocardiogram parameters: estimated ventricular frequency

  Unit: bpm

  Day 1, Day 2, Day 14, Day 15, Day 27, Day 28, Day 39 (End of Treatment), and Day 68 (EoS)

• Changes in 12-lead electrocardiogram parameters: PR

  Unit: milliseconds (ms)

  Day 1, Day 2, Day 14, Day 15, Day 27, Day 28, Day 39 (End of Treatment), and Day 68 (EoS)

• Changes in 12-lead electrocardiogram parameters: QRS

  Unit: milliseconds (ms)

  Day 1, Day 2, Day 14, Day 15, Day 27, Day 28, Day 39 (End of Treatment), and Day 68 (EoS)

• Changes in 12-lead electrocardiogram parameters: QTc

  Unit: milliseconds (ms)

  Day 1, Day 2, Day 14, Day 15, Day 27, Day 28, Day 39 (End of Treatment), and Day 68 (EoS)

• Tolerability of the IMP

  This will be assessed as a binary parameter (tolerable Yes or No): If any of following changes in IMP dosing is deemed necessary, the participant will be classified as 'No': * Dose adjustments prescribed by the Investigator * Dose interruptions prescribed by the Investigator * Discontinuation of treatment

  From Day 1 (start of treatment) through Day 68 [EoS])

Secondary Outcomes (5)

• Change from baseline in the amount and complexity of exercise-induced ventricular ectopic beats as assessed using the ventricular arrythmia (VA) score

  Day 1 (post-dose), Day 14, Day 27, Day 39, and Day 68

• Change from baseline in urine cyclic guanosine monophosphate (cGMP) levels

  Day 1 (post-dose), Day 14, Day 27, Day 39, and Day 68

• Change from baseline in urine cyclic adenosine monophosphate (cAMP) levels

  Day 1 (post-dose), Day 14, Day 27, Day 39, and Day 68

• Change from baseline in plasma cGMP levels

  Day 1 (post-dose), Day 14, Day 27, Day 39, and Day 68

• Change from baseline in plasma cAMP levels

  Day 1 (post-dose), Day 14, Day 27, Day 39, and Day 68

Study Arms (1)

AGP100

EXPERIMENTAL

Within this single arm, three doses levels are planned in an intra-patient dose-escalation design. These will be administered in sequential treatment periods: * Daily dose of 5 mg (1 x 5 mg capsule), oral route, for a planned duration of 13 days (starting dose) * Daily dose of 25 mg (1 x 25 mg capsule), oral route, for a planned duration of 13 days * Daily dose of 50 mg (2 x 25 mg capsules), oral route, for a planned duration of 13 days

Drug: AGP100

Interventions

AGP100 DRUG

AGP100 is a capsule for oral administration. The drug substance is formulated as an encapsulated dry powder blend composed of 5 mg or 25 mg active ingredient and inactive excipients filled into a white, opaque, size 3 hard gelatine capsule. The drug product is a white to light brown solid, with low solubility in water. During study visits, participants will take IMP under supervision of the study staff. Participants will receive with the oral dose together with water. During the rest of each treatment period, participants will self-administer the IMP. Doses should be taken with water, as needed. Participants are to continue to take the IMP once per day until they attend the study visit that starts the next treatment period/the end of study visit.

AGP100

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Signed informed consent prior to any study-related procedures
• Male or female, aged between 18 and 75 years (inclusive)
• Clinical diagnosis of CPVT based on proven RYR2 mutation AND reproducible premature ventricular contraction with exercise or polymorphic or bidirectional ventricular tachycardia with exercise
• Able and willing to undergo exercise testing (bicycle test) AND exhibits exercise-induced ventricular ectopic beats at Screening (at least 1 point on the VA scale)
• On stable, maximum tolerated, dose of non-selective β-blocker for at least 4 weeks before Visit 1. The dosage and choice of β-blocker are to be determined by the patients' physician(s) before entry into the study and must remain unchanged throughout the conduct of the study. Participants taking a stable dose of flecainide for at least 4 weeks, in addition to β-blocker, are also eligible.
• Clinical laboratory evaluations including clinical chemistry, haematology, urinalysis, thyroid function (including thyroid stimulating hormone, triiodothyronine, thyroxine, and free T4) and coagulation testing (activated partial thromboplastin time, and international normalized ratio) within the reference range, unless deemed not clinically significant by the Investigator
• Willing to refrain from strenuous or new exercise for 24 hours before each study visit
• Women of childbearing potential (WOCBP) agree to implement accepted and highly effective means of contraception from study entry until at least 33 days after study drug discontinuation (as per the Clinical Trials Facilitation and Coordination Group guidelines).

You may not qualify if:

• Diagnosis of structural heart disease, including coronary artery disease or heart failure with reduced ejection fraction (left ventricular ejection fraction \<45%)
• Participants who have had arrhythmias causing hemodynamic instability at previous exercise tests (performed while on the current standard of care treatment)
• Participants having a sustained VT (VA score of 5) during the exercise tests performed as part of the screening activities
• Participation in another clinical study with an investigational product or device within 60 days of 5 half-lives prior to Baseline (whichever is longer)
• Medical history of severe anaphylactic reactions to any component(s) of the IMP
• Sensitivity to any of the study treatments, or components thereof, or any drug or other allergy that, in the opinion of the Investigator precludes participation in the study
• Hypersensitivity or contraindication to PDE2 inhibitor drugs
• Use of PDE3, PDE4, or PDE5 inhibitor drugs.
• Participants taking any antiarrhythmic drug(s) except flecainide and non-selective β-blockers
• Significant hypertension (defined as systolic blood pressure of \>160 mmHg and/or diastolic blood pressure of \>95 mmHg). If the blood pressure results are out of range at Screening, the measurements can be repeated on the same day more than once, or at another convenient visit
• Prolonged PR and/or QTc interval at Screening, defined as PR \>240 ms or QTc \>480 ms

Sponsors & Collaborators

• Agiana Pharmaceuticals: lead
• Link Medical Research AS: collaborator
• Viedoc Technologies AB: collaborator
• Vitas AS: collaborator

Study Sites (1)

Department of Cardiology, Oslo University Hospital

Oslo, Norway

RECRUITING

MeSH Terms

Conditions

Polymorphic Catecholaminergic Ventricular Tachycardia

Condition Hierarchy (Ancestors)

Tachycardia, Ventricular; Tachycardia; Arrhythmias, Cardiac; Heart Diseases; Cardiovascular Diseases; Cardiac Conduction System Disease; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Rizwan Hussain, MD PhD

  Agiana Pharmaceuticals AS

  STUDY DIRECTOR

Central Study Contacts

Rizwan Hussain, MD PhD

CONTACT

0047 22 95 85 00; rh@agiana.com

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Masking Details: There is no masking as the study is a single-arm, open-label study. It is an intra-patient dose escalation study where patients first receive a low dose of the drug, then an medium dose, and then a high dose.
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 17, 2025
• First Posted: December 4, 2025
• Study Start: January 2, 2026
• Primary Completion (Estimated): June 30, 2027
• Study Completion (Estimated): June 30, 2027
• Last Updated: December 26, 2025

Record last verified: 2025-12

Data Sharing

• IPD Sharing: Will not share

Locations

NO (1)